Friday, November 13, 2026

Invesco Mortgage Capital carries $5.4B in repo debt as haircut risk looms

Invesco Mortgage Capital Inc. maintains $5.4 billion in repurchase agreement borrowings, exposing the mortgage REIT to rollover risk if repo markets tighten. The company faces potential forced asset sales at unfavorable prices should lenders increase haircut requirements or withdraw funding.

Invesco Mortgage Capital carries $5.4B in repo debt as haircut risk looms
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Invesco Mortgage Capital Inc. operates with $5.4 billion in repurchase agreement borrowings, creating continuous rollover exposure as the mortgage REIT refinances short-term debt against its mortgage-backed securities portfolio.

Repo agreements require daily or weekly renewal. Lenders can demand higher haircuts—the difference between collateral value and loan amount—or exit positions entirely during market stress. The 2020 pandemic spike saw repo haircuts on agency MBS jump from 2-3% to 5-8% within days, forcing multiple REITs into distressed asset sales.

Invesco's portfolio spans residential and commercial mortgage-backed securities, including agency-backed debt. Agency securities carry implicit government backing through Fannie Mae and Freddie Mac, typically securing lower haircuts than private-label MBS. Yet even agency repo markets can seize during volatility spikes.

The mortgage REIT sector maintains leverage ratios between 5:1 and 10:1, amplifying returns during stable periods but magnifying losses when asset values drop or financing costs rise. A 1% decline in MBS values triggers margin calls requiring immediate cash or collateral posting.

Recent Federal Reserve policy shifts add pressure. The central bank reduced its MBS holdings by $35 billion monthly through 2024, withdrawing a major bid from the market. Higher-for-longer interest rates through 2025 compressed REIT net interest margins as short-term repo rates rose faster than yields on existing MBS holdings.

Invesco must maintain relationships with multiple repo counterparties to ensure financing availability. Concentration risk emerges if one or two lenders provide the bulk of funding. Counterparty diversification costs more but reduces rollover vulnerability.

Book value volatility presents another concern. Mortgage REITs mark portfolios to market quarterly. Unrealized losses don't trigger immediate cash needs but erode equity cushions that absorb potential haircut increases. A 10% book value decline on $5.4 billion in repo debt could require $540 million in additional equity or force asset liquidation.

Credit-sensitive MBS and non-agency securities carry higher yields but face steeper haircut increases during risk-off periods. Agency MBS offer more stable financing but lower return spreads in the current rate environment.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com